SDF-1 delivery for treating ischemic tissue
AssigneesThe Cleveland Clinic, Juventas Therapeutics, Inc.
InventorsMarc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
Life of this patent
Estimating the term…
Abstract
A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.
Claims21
An stromal cell-derived factor 1 (SDF-1) plasmid comprising an SDF-1α cDNA sequence having its expression driven by a cytomegalovirus (CMV) enhancer and promoter, CMV-intron A and the RU5 translational enhancer, wherein the plasmid is not contained within a nanoparticle.
Dependencies are inferred from the claim text.